Ojas Therapeutics is advancing oral therapies for rare immune diseases, addressing a critical gap in treatment options for patients with limited alternatives. The company focuses on developing small-molecule drugs that can be administered orally, potentially improving patient compliance and quality of life compared to injectable biologics. Their pipeline targets specific immune-mediated conditions with high unmet medical need.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with rare immune diseases often face limited treatment options, with many existing therapies requiring frequent injections or infusions that are burdensome and reduce quality of life. The scarcity of oral alternatives for these conditions leaves significant gaps in care, particularly for chronic diseases that demand long-term management.
Solution
Ojas Therapeutics is developing oral small-molecule therapies designed to treat rare immune diseases with greater convenience and accessibility than traditional biologic injectables. By leveraging advanced medicinal chemistry and immunology expertise, the company aims to create drugs that modulate specific immune pathways implicated in disease pathogenesis. Their oral formulations are intended to offer comparable efficacy to biologics while simplifying administration and improving patient adherence. The pipeline focuses on conditions where oral delivery could meaningfully transform the treatment experience and outcomes.
Target Audience
Primary customers are patients with rare immune diseases and the healthcare providers who treat them, including immunologists, rheumatologists, and specialists in rare disease centers.
Features
- Oral small-molecule drug candidates targeting validated immune pathways for rare diseases
- Proprietary formulation technology designed to enhance bioavailability and stability of oral therapies
- Pipeline prioritized around conditions with high unmet need and clear regulatory pathways
- Patient-centric approach emphasizing reduced treatment burden compared to injectable biologics